These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24001100)

  • 1. Letter: rapid infliximab infusion is not always safe--authors' reply.
    Neef H; Adler J
    Aliment Pharmacol Ther; 2013 Oct; 38(7):844-5. PubMed ID: 24001100
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: rapid infliximab infusion is not always safe.
    Lankarani KB
    Aliment Pharmacol Ther; 2013 Oct; 38(7):844. PubMed ID: 24001101
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: The feasibility and safety of accelerated infliximab infusions in patients with inflammatory bowel disease.
    Nantes Ó; Rodríguez C; Basterra M; Gómez M; Cambra K; Ibáñez B; Fernandez-Urien I; Arín A
    Aliment Pharmacol Ther; 2014 Feb; 39(4):444-5. PubMed ID: 24447320
    [No Abstract]   [Full Text] [Related]  

  • 4. Meta-analysis: rapid infliximab infusions are safe.
    Neef HC; Riebschleger MP; Adler J
    Aliment Pharmacol Ther; 2013 Aug; 38(4):365-76. PubMed ID: 23815183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experiences with infliximab in the treatment of active rheumatoid arthritis and spondyloarthropathy].
    Dahlin J; Sørensen SF
    Ugeskr Laeger; 2003 Nov; 165(48):4646-9. PubMed ID: 14677464
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of inflammatory diseases: safety of long-term use of infliximab].
    Schaible TF
    Presse Med; 2001 Mar; 30(12):610-3. PubMed ID: 11317923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
    Kapetanovic MC; Larsson L; Truedsson L; Sturfelt G; Saxne T; Geborek P
    Arthritis Res Ther; 2006; 8(4):R131. PubMed ID: 16869978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single infusion of infliximab increases the serum endostatin level in patients with rheumatoid arthritis.
    Kucharz EJ; Gozdzik J; Kopec M; Kotulska A; Lewicki M; Pieczyrak R; Widuchowska M; Zakliczynska H; Szarzynska-Ruda M; Zycinska-Debska E
    Clin Exp Rheumatol; 2003; 21(2):273-4. PubMed ID: 12747296
    [No Abstract]   [Full Text] [Related]  

  • 10. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
    Verma AM; Patel A; Subramanian S; Smith PJ
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):88-89. PubMed ID: 33444534
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study.
    Nikas SN; Temekonidis TI; Zikou AK; Argyropoulou MI; Efremidis S; Drosos AA
    Ann Rheum Dis; 2004 Jan; 63(1):102-3. PubMed ID: 14672902
    [No Abstract]   [Full Text] [Related]  

  • 12. Relocating rheumatology patients to a new infusion center at Duke: a case study.
    Baker JJ; Leovic TM; O'Connor CA; Pierce CA
    Health Care Manag (Frederick); 2003; 22(2):159-69. PubMed ID: 12785554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Are anti-TNFAb indicated in systemic necrotizing vasculitides?].
    Guillevin L
    Rev Med Interne; 2005 Oct; 26(10):769-70. PubMed ID: 16039017
    [No Abstract]   [Full Text] [Related]  

  • 14. How to dose infliximab in rheumatoid arthritis: new data on a serious issue.
    van Vollenhoven RF
    Ann Rheum Dis; 2009 Aug; 68(8):1237-9. PubMed ID: 19605741
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis.
    Marchesoni A; Sarzi Puttini P; Gorla R; Caporali R; Arnoldi C; Atzeni F; Vianelli M; Pallavicini FB
    Clin Exp Rheumatol; 2005; 23(6):916-7. PubMed ID: 16396721
    [No Abstract]   [Full Text] [Related]  

  • 16. Monoclonal Antibodies.
    Anderson PO
    Breastfeed Med; 2016 Apr; 11():100-1. PubMed ID: 26982884
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral neuropathy during infliximab therapy for rheumatoid arthritis.
    El Aidli S; Gaïes E; Cherif F; Zaiem A; Daghfous R; Lakhal M
    Presse Med; 2014 Sep; 43(9):1012-4. PubMed ID: 24742611
    [No Abstract]   [Full Text] [Related]  

  • 19. Timing of DAS28 in infliximab therapy.
    Armstrong DJ; Bruce IN
    Rheumatology (Oxford); 2005 Sep; 44(9):1203-4; author reply 1204. PubMed ID: 15870143
    [No Abstract]   [Full Text] [Related]  

  • 20. Reactions to infliximab in patients with rheumatoid arthritis.
    Sakellariou GT; Chatzigiannis I
    J Rheumatol; 2005 Jul; 32(7):1411-2. PubMed ID: 15996088
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.